The desirability of targeting S-phase as a mode of action of breast cancer therapeutics is underlined by the topoisomerase I (TOP1) inhibitor irinotecan, which is a clinically effective pharmaceutical for advanced and metastatic breast cancer [53]. The gene discussed is TOP1; the disease is breast carcinoma.